Neuberger Berman Group
IMNM icon

Neuberger Berman Group’s Immunome IMNM Stock Holding History

Neuberger Berman Group’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-19,444
Closed -$86K – 1833
2022
Q3 		$86K Hold
19,444
– – ﹤0.01% 1779
2022
Q2 		$62K Hold
19,444
– – ﹤0.01% 1806
2022
Q1 		$110K Hold
19,444
– – ﹤0.01% 1844
2021
Q4 		$252K Hold
19,444
– – ﹤0.01% 1768
2021
Q3 		$473K Hold
19,444
– – ﹤0.01% 1481
2021
Q2 		$336K Buy
+19,444
New +$429K ﹤0.01% 1579

Other funds holding IMNM

AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
MFG
Magnus Financial Group New York $1.41B AUM 23.4% 1-Year Est. Return

Neuberger Berman Group's IMNM Position: Q4 2022 in Review

Neuberger Berman Group sold out of Immunome (IMNM) in Q4 2022, closing a stake of 19,444 shares — an estimated $86K sold.

Neuberger Berman Group first reported a position in IMNM in Q2 2021 and held it in 6 quarters. The position peaked at $473K in Q3 2021. 28 funds tracked by Wall St. Rank hold IMNM as of Q4 2022.

  • Neuberger Berman Group reported no remaining Immunome position as of Q4 2022 after selling out during the quarter.
  • Neuberger Berman Group sold 19,444 Immunome shares in Q4 2022, an estimated $86K.
  • Neuberger Berman Group first reported a position in Immunome in Q2 2021 and held it in 6 quarters.
  • Neuberger Berman Group's Immunome position peaked at $473K in Q3 2021.
  • 28 funds tracked by Wall St. Rank held Immunome as of Q4 2022.

Based on Neuberger Berman Group's 13F filing for Q4 2022, filed 13 Feb 2023.